This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a phase 1 safety study, where the primary objective is to determine the biodistribution of In-AHN-12 in patients witrh refractory CD45+ leukemia. Secondary objectives are to determine the maximum tolderated dose (MTD) of Y-AHN-12, the human anti-mouse antibody (HAMA) response, and preliminarily define the antitumor activity of Y-AHN-12.
Showing the most recent 10 out of 724 publications